Sherlock Biosciences is an Engineering Biology company dedicated to making diagnostic testing better, faster and more affordable.
Sherlock's goal is to address significant unmet needs in infectious disease, oncology, agriculture, and other areas to transform diagnostic testing and global public health.
Sherlock Biosciences was co-founded in 2019 by Rahul Dhanda, James Collins, Pardis Sabeti, and David R. Walt. The company is headquartered in Cambridge, Massachusetts.
Sherlock leverages its engineering biology tools, CRISPR-based SHERLOCK™ and synthetic biology-based INSPECTR™ to bring together the accuracy of PCR with the convenience and simplicity of antigen tests for molecular diagnostics at the point-of-need.
SHERLOCK and INSPECTR can be used in virtually any setting without complex instrumentation, opening up a wide range of potential applications in areas including precision oncology, infection identification, food safety, at-home tests, and disease detection in the field.
Sherlock received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA), in May 2020, for its Sherlock™ CRISPR SARS-CoV-2 kit, the first FDA-authorized use of CRISPR technology.
Sherlock is backed by Bill & Melinda Gates Foundation, Novalis LifeSciences, Northpond Ventures, Baidu Ventures, Illumina Ventures, Albany Capital, Catalio Capital Management, and others. The company raised $80M in Series B round on Mar 08, 2022. This brings Sherlock's total funding to $141M to date.